Mark R Litzow
Overview
Explore the profile of Mark R Litzow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
411
Citations
10283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baranwal A, Langer K, Gannamani V, Rud D, Cibich A, Saygin C, et al.
Blood Adv
. 2025 Mar;
PMID: 40085959
Allogeneic stem cell transplant (alloHCT) is considered for all patients with myeloid neoplasms (MN) harboring TP53-mutations (TP53mut). The aim of this international study across 7 transplant centers in USA and...
2.
Shah M, Hung MBBS FRACP FRCPA K, Baranwal A, Kutyna M, Al-Kali A, Toop C, et al.
Blood Adv
. 2025 Mar;
PMID: 40085954
This retrospective analysis aimed to provide evidence-based risk-stratification of TP53-mutated (TP53mut) myeloid neoplasms (MN). Of 580 MN harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92...
3.
Csizmar C, Litzow M, Saliba A
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075627
Despite notable progress in managing B-cell acute lymphoblastic leukemia (B-ALL) over recent decades, particularly in pediatric cohorts where the 5-year overall survival (OS) reaches 90%, outcomes for the 10-15% with...
4.
Wen J, Li A, Wang Z, Guo X, Zhang G, Litzow M, et al.
Front Pharmacol
. 2025 Mar;
16:1536388.
PMID: 40051569
Arsenic trioxide (ATO) has shown substantial efficacy in the treatment of patients with acute promyelocytic leukemia, and the utilization of ATO as a potential treatment for other tumors is currently...
5.
Acosta-Medina A, Sridharan M, Go R, Moyer A, Leung N, Willrich M, et al.
Am J Hematol
. 2025 Mar;
PMID: 40047384
Transplant-associated thrombotic microangiopathy (TA-TMA) is an endothelial dysfunction syndrome observed after allogeneic hematopoietic cell transplant (alloHCT). Our aim was to externally validate the impact of high-risk features on the clinical...
6.
Kusne Y, Badar T, Lasho T, Marando L, Mangaonkar A, Finke C, et al.
Br J Haematol
. 2025 Mar;
PMID: 40040251
Germline variants in DDX41 (DDX41-germline predisposition syndrome [GPS]) are associated with predisposition to haematological malignancies (HM), including lymphoid and myeloid neoplasms (MN). We retrospectively analysed the clinical and molecular features...
7.
Jillella A, Lee S, Altman J, Luger S, Tallman M, Foran J, et al.
JAMA Oncol
. 2025 Feb;
PMID: 40014329
Importance: Acute promyelocytic leukemia (APL) is an acute illness that presents with cytopenia, infections, and disseminated intravascular coagulation. Achieving remission has been shown to make a major difference in patient...
8.
Johnson I, Ilyas R, McCullough K, Al-Kali A, Alkhateeb H, Begna K, et al.
Haematologica
. 2025 Feb;
PMID: 40013400
Not available.
9.
10.
Escherich C, Moriyama T, Li Z, Hsiao Y, Hsiao Y, Yang W, et al.
Blood
. 2025 Jan;
145(11):1182-1194.
PMID: 39791601
Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there is wide interpatient variability in treatment response, and the genetic basis of...